T. Ribeiro

U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer

M. Nobre, G. Harada, T. Ribeiro, 2019, International Journal of Technology Assessment in Health Care.

Evaluation of the initial response in clinical trial efforts for COVID-19 in Brazil.

A. Stein, F. Diaz-Quijano, D. O. Melo, 2021, Revista brasileira de epidemiologia = Brazilian journal of epidemiology.

Building capacity in evidence-based medicine in low-income and middle-income countries: problems and potential solutions

D. Umpierre, P. Gill, G. Richards, 2019, BMJ Evidence-Based Medicine.

New lung cancer treatments in Brazil, inequalities in patient access between the private and public health systems and differences in market access compared with the USA

S. Kelles, M. Nobre, D. O. Melo, 2020 .

Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018

C. Wayant, L. Buss, M. Nobre, 2020, PloS one.

Factors associated with higher quality of clinical practice guidelines and their recommendations for the pharmacological treatment of depression: a systematic review

D. Telles-Correia, R. Fráguas, A. Stein, 2023, BMJ Open.

Medication-related inpatient falls: a critical review

Flávia de Oliveira Motta Maia, T. Ribeiro, E. Ribeiro, 2018, Brazilian Journal of Pharmaceutical Sciences.

Single-arm clinical trials that supported FDA Accelerated Approvals have modest effect sizes and at high risk of bias.

I. Hozo, B. Djulbegovic, Charles L. Bennett, 2022, Journal of clinical epidemiology.